衍生品CELASTROL是一种YAP抑制剂,在全身性硬化症中具有抗纤维作用
Pratyusha Chitturi1, Shiwen Xu2, Bahja Ahmed Abdi2
1College of Dentistry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Annals of the rheumatic diseases
|June 16, 2023
概括
塞拉斯特是一种YAP1抑制剂,通过向机械传导通路来减少系统性硬化 (SSc) 中的纤维化. 这项研究确定了SSc皮肤纤维化中涉及的特定细胞,表明塞拉斯特是潜在的治疗剂.
科学领域:
- 纤维化研究纤维化.
- 机械生物学 机械生物学
- 皮肤病学 皮肤病学
背景情况:
- 系统性硬化症 (SSc) 涉及到由机械传导信号驱动的广泛组织纤维化.
- 在SSc纤维细胞中,YAP1通路被激活,这表明它在疾病发病过程中的潜在作用.
- 了解皮肤纤维化中的细胞对于开发向疗法至关重要.
研究的目的:
- 研究YAP1抑制剂塞拉斯特在缓解SSc相关纤维化的治疗潜力.
- 为了识别SSc.中皮肤纤维化发展所涉及的特定细胞.
- 探索塞拉斯特对YAP1激活和纤维化基因表达的影响.
主要方法:
- 来自健康患者和SSc患者的人体皮肤纤维细胞被TGFβ1和/或切拉斯特醇治疗.
- 蓝素诱导的SSc小鼠模型被用于评估体内纤维化.
- 用RNA测序,PCR,西斑,ELISA和组织学分析了基因表达,蛋白质水平和YAP1局部化.
主要成果:
- 塞拉斯特抑制了纤维细胞中TGFβ1诱导的SSc类基因表达.
- 塞拉斯特改善了SSc患者衍生的纤维细胞中的纤维化表型.
- 在体内,切拉斯特降低了白血素诱导的纤维化标志物,并抑制了YAP1核局部化.
结论:
- 塞拉斯特有效地对抗YAP1通路,减少SSc皮肤纤维化.
- 该研究澄清了纤维化期间激活的特定皮肤.
- 塞拉斯特代表了治疗SSc皮肤纤维化的一个有前途的治疗候选者.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357
01:19Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
204
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
204
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
317
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
317